Kara L. Vine

2.7k total citations
57 papers, 2.1k citations indexed

About

Kara L. Vine is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Kara L. Vine has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Kara L. Vine's work include Protease and Inhibitor Mechanisms (11 papers), Amyotrophic Lateral Sclerosis Research (7 papers) and Peptidase Inhibition and Analysis (7 papers). Kara L. Vine is often cited by papers focused on Protease and Inhibitor Mechanisms (11 papers), Amyotrophic Lateral Sclerosis Research (7 papers) and Peptidase Inhibition and Analysis (7 papers). Kara L. Vine collaborates with scholars based in Australia, United Kingdom and United States. Kara L. Vine's co-authors include Marie Ranson, Julie M. Locke, John B. Bremner, Lidia Matesic, Danielle Skropeta, Stephen G. Pyne, Darren N. Saunders, Lisa Belfiore, Morteza Aghmesheh and Kristofer J. Thurecht and has published in prestigious journals such as Advanced Materials, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Kara L. Vine

55 papers receiving 2.0k citations

Peers

Countries citing papers authored by Kara L. Vine

Since Specialization

Citations

This map shows the geographic impact of Kara L. Vine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kara L. Vine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kara L. Vine more than expected).

Fields of papers citing papers by Kara L. Vine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kara L. Vine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kara L. Vine. The network helps show where Kara L. Vine may publish in the future.

Co-authorship network of co-authors of Kara L. Vine

This figure shows the co-authorship network connecting the top 25 collaborators of Kara L. Vine. A scholar is included among the top collaborators of Kara L. Vine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kara L. Vine. Kara L. Vine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancer 2025 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), Paul A. Beavis, Junyun Lai, Gordon G. Wallace, (unknown), (unknown), (unknown), Daniel Brungs, Morteza Aghmesheh, Kara L. Vine	0
2	Development of a targeted BioPROTAC degrader selective for misfolded SOD1 2025 ·Nature Communications ·(unknown), Rachael Bartlett, (unknown), (unknown), Natalie E. Farrawell, (unknown), Fabien Delerue, Lars M. Ittner, Kara L. Vine, Heath Ecroyd, Neil R. Cashman, Darren N. Saunders, Luke McAlary, Jeremy S. Lum, Justin J. Yerbury	0
3	Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy 2024 ·Journal of Controlled Release ·(unknown), Amal J. Sivaram, Gary Cowin, (unknown), Luke McAlary, Jeremy S. Lum, Nicholas L. Fletcher, (unknown), Joshua D. Simpson, Liyu Chen, Joanna M. Wasielewska, Edward Byrne, John Finnie, Jim Manavis, Anthony R. White, Justin J. Yerbury, Kristofer J. Thurecht, Kara L. Vine	10
4	Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice 2024 ·Clinical & Translational Immunology ·(unknown), (unknown), (unknown), Kara L. Vine, (unknown), (unknown), Stephen I. Alexander, Ronald Sluyter, Debbie Watson	2
5	Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds 2024 ·Journal of Controlled Release ·(unknown), Marie Ranson, Morteza Aghmesheh, Ronald Sluyter, Kara L. Vine	13
6	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model 2023 ·PLoS Computational Biology ·Adrianne L. Jenner, Wayne Kelly, (unknown), Robyn P. Araujo, (unknown), (unknown), (unknown), Peter Kim, (unknown), Kara L. Vine	3
7	3D-Printed Coaxial Hydrogel Patches with Mussel-Inspired Elements for Prolonged Release of Gemcitabine 2021 ·Polymers ·Sepehr Talebian, In Kyong Shim, Javad Foroughi, Gorka Orive, Kara L. Vine, Song Cheol Kim, Gordon G. Wallace	15
8	CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background 2021 ·Scientific Reports ·Jeremy S. Lum, (unknown), Natalie E. Farrawell, Luke McAlary, (unknown), (unknown), (unknown), Kara L. Vine, Tim Karl, (unknown), Lachlan E. McInnes, Sara Nikseresht, Paul S. Donnelly, Peter J. Crouch, Justin J. Yerbury	16
9	Ubiquitin Homeostasis Is Disrupted in TDP-43 and FUS Cell Models of ALS 2020 ·iScience ·Natalie E. Farrawell, Luke McAlary, Jeremy S. Lum, (unknown), Sadaf T. Warraich, Ian P. Blair, Kara L. Vine, Darren N. Saunders, Justin J. Yerbury	38
10	Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma 2019 ·Pathology ·Daniel Brungs, (unknown), (unknown), Martin Illemann, (unknown), Nicholas Hirst, (unknown), Winston Liauw, Kara L. Vine, (unknown), Martin Carolan, Therese M. Becker, Morteza Aghmesheh, Marie Ranson	10
11	SOD1A4V aggregation alters ubiquitin homeostasis in a cell model of ALS 2018 ·Journal of Cell Science ·Natalie E. Farrawell, (unknown), Kristen A. Mitchell, (unknown), Luke McAlary, Prajwal Ciryam, Kara L. Vine, Darren N. Saunders, Justin J. Yerbury	40
12	Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer 2018 ·World Journal of Gastroenterology ·Daniel Brungs, David T. Lynch, Alison W. S. Luk, (unknown), Marie Ranson, Morteza Aghmesheh, Kara L. Vine, Martin Carolan, (unknown), Paul de Souza, Therese M. Becker	19
13	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities 2018 ·Journal of Controlled Release ·Lisa Belfiore, Darren N. Saunders, Marie Ranson, Kristofer J. Thurecht, Gert Storm, Kara L. Vine	244
14	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer 2017 ·Oncogene ·(unknown), (unknown), Claire Vennin, James R. W. Conway, Kara L. Vine, Mark Pinese, Mark J. Cowley, (unknown), Morghan C. Lucas, David Herrmann, Amr H. Allam, Marina Pajic, Jennifer P. Morton, Andrew V. Biankin, Marie Ranson, Paul Timpson, Darren N. Saunders	77
15	N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1βRelease from Murine Macrophages 2016 ·Mediators of Inflammation ·Ronald Sluyter, Kara L. Vine	8
16	TCTP is induced early in colorectal cancer, it is translationally regulated via the Akt/mTORC1 pathway, and it contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin 2015 ·FEBS Journal ·Ulrich‐Axel Bommer, Kara L. Vine, Valentina Iadevaia, Lisa Belfiore, Martin Engel, (unknown), (unknown), (unknown), (unknown), Christopher G. Proud	1
17	Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms 2012 ·Nuclear Medicine and Biology ·Marie Ranson, Paula Berghofer, Kara L. Vine, Ivan Greguric, (unknown), Andrew Katsifis	3
18	Selective targeting of 2′-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro 2010 ·Bioorganic & Medicinal Chemistry Letters ·Kara L. Vine, Julie M. Locke, John B. Bremner, Stephen G. Pyne, Marie Ranson	7
19	Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008 2009 ·Anti-Cancer Agents in Medicinal Chemistry ·Kara L. Vine, Lidia Matesic, Julie M. Locke, Marie Ranson, Danielle Skropeta	238
20	In vitro cytotoxicity evaluation of some substituted isatin derivatives 2006 ·Bioorganic & Medicinal Chemistry ·Kara L. Vine, Julie M. Locke, Marie Ranson, Stephen G. Pyne, John B. Bremner	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact